帕金森病预防试验应纳入哪些人群?支持复合前驱期队列的理由
本文论述帕金森病前驱期单一特征因敏感性、特异性和阳性预测值低而不适于早期识别和预防试验入组,提出由多种共存前驱特征构成的复合队列更能代表高危人群、支持跨特征模式评估干预效果并可获得更大样本量。识别前驱期个体的关键挑战是对前驱期帕金森病自然史了解甚少,需更好理解常见前驱特征模式并预测进展和表型转化的概率。现有队列研究和行政数据库研究正开始解决这些问题,但尚需在大型人群样本中进一步纵向分析以提供有说服力的策略。
要点
- 单一前驱特征因敏感性、特异性和阳性预测值低,多数情况下不足以用于早期识别和预防试验入组。
- 复合队列由多种共存前驱特征个体组成,更代表帕金森病高危人群,可评估不同前驱特征模式的干预效果。
- 需更好理解常见前驱特征模式并预测进展和表型转化概率,尚需大型人群样本的进一步纵向分析。
核心结论
- 复合前驱期队列是开展前驱期帕金森病研究和最终预防试验的重要资源,但识别前驱期个体的关键挑战是对前驱期帕金森病自然史了解甚少。
- 尚需在大型人群样本中进一步纵向分析,以提供有说服力和确定性的预防试验入组个体识别策略。
研究设计与样本
- 本文为论述性文章,未报告系统检索范围或原始研究样本。
主要发现
- 单一前驱特征因敏感性、特异性和阳性预测值低,多数情况下不足以用于早期疾病检测和预防试验入组。
- 复合队列更能代表帕金森病高危人群,允许评估干预在不同前驱特征模式个体中的效果,能够产生更大样本量,并捕获不同前驱期阶段的个体。
- 现有队列研究和行政数据库研究正开始解决前驱期自然史问题,但尚需大型人群样本的进一步纵向分析。
局限性
- 原文指出对前驱期帕金森病自然史了解甚少,是识别复合队列和预防试验入组个体的关键挑战。
- 原文指出尚需在大型人群样本中进一步纵向分析,以提供有说服力和确定性的预防试验入组策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Significant progress has been made in expanding our understanding of prodromal Parkinson disease (PD), particularly for recognition of early motor and nonmotor signs and symptoms. Although identification of these prodromal features may improve our understanding of the earliest stages of PD, they are individually insufficient for early disease detection and enrollment of participants in prevention trials in most cases because of low sensitivity, specificity, and positive predictive value. Composite cohorts, composed of individuals with multiple co-occurring prodromal features, are an important resource for conducting prodromal PD research and eventual prevention trials because they are more representative of the population at risk for PD, allow investigators to evaluate the efficacy of an intervention across individuals with varying prodromal feature patterns, are able to produce larger sample sizes, and capture individuals at different stages of prodromal PD. A key challenge in identifying individuals with prodromal disease for composite cohorts and prevention trial participation is that we know little about the natural history of prodromal PD. To move toward prevention trials, it is critical that we better understand common prodromal feature patterns and be able to predict the probability of progression and phenoconversion. Ongoing research in cohort studies and administrative databases is beginning to address these questions, but further longitudinal analyses in a large population-based sample are necessary to provide a convincing and definitive strategy for identifying individuals to be enrolled in a prevention trial.
引用
- Molsberry SA, Hughes KC, Schwarzschild MA, et al. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts. Neurology. 2022. PMID: 35970591. doi:10.1212/WNL.0000000000200788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。